Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.085
+0.025 (0.82%)
Nov 21, 2024, 11:28 AM EST - Market open
Xeris Biopharma Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 187.36 | 163.91 | 110.25 | 49.59 | 20.44 | 2.72 | Upgrade
|
| Revenue Growth (YoY) | 22.72% | 48.68% | 122.32% | 142.67% | 650.73% | 12.34% | Upgrade
|
| Cost of Revenue | 34.92 | 28.65 | 22.63 | 13.32 | 9.33 | 1.6 | Upgrade
|
| Gross Profit | 152.44 | 135.27 | 87.61 | 36.27 | 11.11 | 1.12 | Upgrade
|
| Selling, General & Admin | 160.91 | 146.1 | 136.26 | 116.06 | 73.73 | 63.06 | Upgrade
|
| Research & Development | 25.85 | 22.34 | 20.97 | 25.16 | 18.92 | 60.44 | Upgrade
|
| Operating Expenses | 197.6 | 179.28 | 168.07 | 141.77 | 92.65 | 123.5 | Upgrade
|
| Operating Income | -45.17 | -44.01 | -80.45 | -105.5 | -81.55 | -122.38 | Upgrade
|
| Interest Expense | -29.8 | -26.61 | -14.1 | -7.18 | -10.66 | -7.16 | Upgrade
|
| Interest & Investment Income | 4.26 | 3.49 | 2.76 | 0.73 | 1.47 | 2.81 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | 0 | 1.76 | -0.7 | -0.01 | 0.69 | Upgrade
|
| EBT Excluding Unusual Items | -70.71 | -67.13 | -90.03 | -112.66 | -90.75 | -126.04 | Upgrade
|
| Merger & Restructuring Charges | - | - | -1.49 | -9.66 | -2 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.26 | 1.26 | -0.18 | -0.41 | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | 1.5 | - | Upgrade
|
| Other Unusual Items | 3.83 | 2.36 | -4.38 | - | - | - | Upgrade
|
| Pretax Income | -65.62 | -63.5 | -96.08 | -122.73 | -91.25 | -126.04 | Upgrade
|
| Income Tax Expense | -2.5 | -1.25 | -1.42 | - | -0.11 | -0.46 | Upgrade
|
| Net Income | -63.11 | -62.26 | -94.66 | -122.73 | -91.14 | -125.58 | Upgrade
|
| Net Income to Common | -63.11 | -62.26 | -94.66 | -122.73 | -91.14 | -125.58 | Upgrade
|
| Shares Outstanding (Basic) | 144 | 138 | 136 | 79 | 43 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 144 | 138 | 136 | 79 | 43 | 26 | Upgrade
|
| Shares Change (YoY) | 5.01% | 1.51% | 71.62% | 85.32% | 63.32% | 116.75% | Upgrade
|
| EPS (Basic) | -0.44 | -0.45 | -0.70 | -1.55 | -2.14 | -4.81 | Upgrade
|
| EPS (Diluted) | -0.44 | -0.45 | -0.70 | -1.55 | -2.14 | -4.81 | Upgrade
|
| Free Cash Flow | -32.27 | -49.29 | -103.42 | -96.62 | -80.94 | -105.45 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.36 | -0.76 | -1.22 | -1.90 | -4.04 | Upgrade
|
| Gross Margin | 81.36% | 82.52% | 79.47% | 73.14% | 54.35% | 41.11% | Upgrade
|
| Operating Margin | -24.11% | -26.85% | -72.97% | -212.74% | -399.05% | -4495.96% | Upgrade
|
| Profit Margin | -33.69% | -37.98% | -85.86% | -247.48% | -446.00% | -4613.52% | Upgrade
|
| Free Cash Flow Margin | -17.22% | -30.07% | -93.80% | -194.84% | -396.06% | -3874.10% | Upgrade
|
| EBITDA | -33.06 | -31.68 | -68.21 | -103.62 | -80.08 | -121.3 | Upgrade
|
| EBITDA Margin | -17.65% | -19.33% | -61.87% | -208.95% | - | - | Upgrade
|
| D&A For EBITDA | 12.1 | 12.33 | 12.24 | 1.88 | 1.47 | 1.08 | Upgrade
|
| EBIT | -45.17 | -44.01 | -80.45 | -105.5 | -81.55 | -122.38 | Upgrade
|
| EBIT Margin | -24.11% | -26.85% | -72.97% | -212.74% | - | - | Upgrade
|
| Revenue as Reported | 187.36 | 163.91 | 110.25 | 49.59 | 20.44 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.